Clinical Trials Browser

Phase 2 × ulixertinib × Other solid neoplasm × Clear all

NCT04488003 2024-06-04

Study of Ulixertinib for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations

Phase 2 Terminated

104 enrolled 13 charts

Other solid neoplasm

Advanced Solid Tumor